Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2017

Historically, biguanides and sulfonylureas were the most heavily prescribed T2D drug classes. However, the DPP-IV inhibitors have recently overtaken sulfonylureas to become the second-most heavily prescribed drug class. Numerous branded agents jostle for position as second-line treatment options, including the DPP-IV inhibitors, the SGLT2inhibitors Jardiance, Invokana and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Adding to the complexity of the market dynamics, the biosimilar insulin Basaglar is also picking up significant patient share.

Questions answered:

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed type 2 diabetes patients?
  • What proportion of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of type 2 diabetes patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with type 2 diabetes?

Key analysis provided: 

  • Brand usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow charts

Markets covered: United States

Primary research:  Longitudinal patient-level claims data analysis

Login to access report